1. Home
  2. DJT vs TYRA Comparison

DJT vs TYRA Comparison

Compare DJT & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trump Media & Technology Group Corp.

DJT

Trump Media & Technology Group Corp.

HOLD

Current Price

$8.35

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$25.02

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DJT
TYRA
Founded
2021
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DJT
TYRA
Price
$8.35
$25.02
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$47.50
AVG Volume (30 Days)
4.8M
616.3K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,682,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.76
N/A
52 Week Low
$6.96
$9.96
52 Week High
$18.97
$40.65

Technical Indicators

Market Signals
Indicator
DJT
TYRA
Relative Strength Index (RSI) 39.84 32.00
Support Level $8.10 $24.77
Resistance Level $8.77 $32.82
Average True Range (ATR) 0.63 1.70
MACD -0.22 -0.68
Stochastic Oscillator 7.88 2.12

Price Performance

Historical Comparison
DJT
TYRA

About DJT Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: